—
C+
C+ The full Closelooknet — membership. Open the C+ overview

ICON PLC (ICLR) — chart, structure and Closelooknet read

The Closelooknet read

ICON runs outsourced clinical trial and drug development work for pharmaceutical, biotech and device companies, covering the full path from early compound testing through Phase I-IV studies. It also offers laboratory testing, data analysis, site and patient access, and post-approval commercial support.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

The desk on ICLR

What this diary said about ICON PLC, what it holds and what would change its view — in its own words, dated. Investment diary, not advice.

What we said

Signals for this name

Every Closelooknet reading that exists for ICLR, from the same nightly bakes the boards use. Research diary readings, not advice.

Mentioned on Closelooknet 2 pieces · newest: Report, “Google and RSI — The Loop Nobody Has Closed” (2026-09-13)

Mentioned on Closelooknet

Where ICLR appears in the diary — 2 pieces, newest first. Every link is our own writing.

Long reads

Dailies

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 46/100 · S&P 500 fund at 50, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-02
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in US: +3.0% week · +11.1% month · +14.3% quarter · +26.9% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-02
  • Sovereign pressure Index -1.66 · down 2.24 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-10-30
How it trades on rate days beta 0.17 to TLT · on the worst bond days it held up better than the market

How it trades on rate days

How ICLR has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.17 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), ICON PLC moved 0.17% on average · correlation 0.02 · higher than 13% of US names
  • Beta, last 3 months −0.38 less rate-sensitive lately than over the year
  • On the 10 worst bond days +0.11% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +6.10% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Diagnostics & Research · US · 8 names with week and year-to-date

Peer group

Diagnostics & Research · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against ICLR on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — ICON PLC

ICLR in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
ICON runs outsourced clinical trial and drug development work for pharmaceutical, biotech and device companies, covering the full path from early compound testing through Phase I-IV studies. It also offers laboratory testing, data analysis, site and patient access, and post-approval commercial support. It is headquartered in Dublin and serves clients across pharmaceuticals, biotechnology, devices and public health bodies.
Where it sits in the stack
ICON carries no seat in our Rubin or Halo indices and sits outside the AI build-out sleeves; the diary places it in the healthcare sector, under diagnostics and research, alongside other clinical research organisations rather than any chip, compute or data-centre layer.
Who it is priced against
Closelooknet's peer group for ICON is not defined in our records; the market commonly compares it with IQVIA as another large clinical research organisation.
Why Closelooknet tracks it
ICON carries a Closelooknet score, but only one module has been scored so far, so the reading is still being built. It has no index seat and appears in two editions, though both quotes concern the ICLR machine-learning conference rather than the company itself, a name overlap rather than dedicated coverage of its business.
What the diary watches
The diary watches whether pharmaceutical and biotech sponsors keep outsourcing trial management at the same pace, since ICON's order book depends on that spending holding up.

ICON PLC (ICLR) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 48/100 composite (momentum 93, quality 34, valuation 48) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 10 analyst actions on the wire · latest: price target by Mizuho, 2026-10-30

The Street on this name

Analyst actions and the latest print for ICLR from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target Mizuho — target 228 Target set to $228 (+8.6% to spot) 2026-10-30
  • Price target BMO Capital — target 235 Target set to $235 (+9.1% to spot) 2026-10-29
  • Price target Deutsche Bank — target 250 from 200 Target raised to $250 from $200 (+14.9% to spot) 2026-10-29

10 actions on the analyst wire since 2026-08-13: 10 target changes. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 750 m USD in FY2025

Dividends and capital return

What ICLR pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 750 m USD 5.3% of today's market value
  • Share count −4.9% in FY2025 102 m USD of stock-based compensation in the year
  • Capital returned 750 m USD · 87% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-01

Quick answers

What is ICON PLC (ICLR)?

ICON PLC trades as ICLR on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-01.

Is ICLR in a Closelooknet index?

Not currently — ICON PLC is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-01.

What is ICON PLC's Closelooknet composite score?

48 out of 100, with momentum 93, quality 34 and valuation 48 sub-scores, as of 2026-11-01. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ICLR trade against its moving averages?

ICON PLC trades 22.9% above its 50-day and 45.0% above its 200-day moving average (18.3% above its 20-day). As of 2026-10-30 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does ICON PLC compare with its peers?

Against its peer group (Diagnostics & Research · US), ICON PLC (ICLR) sits 3.5% below its 52-week high, 22.9% above its 50-day average; Medpace Holdings Inc (MEDP) is 6.0% below, IDEXX Laboratories Inc (IDXX) is 28.4% below, Illumina Inc (ILMN) is 23.7% below, as of 2026-10-30. Put any of them next to ICLR in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does ICON PLC trade when bond yields rise?

Over the past year ICON PLC had a beta of 0.17 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 13% of US names. On the 10 sessions in which long bonds fell most it moved +0.11% on average, against −0.74% for the S&P 500. As of 2026-10-30; The "How it trades on rate days" block on this page carries the lines.

Where has Closelooknet written about ICON PLC?

ICON PLC appears in 2 Closelooknet pieces as of 2026-11-01, most recently Report: Google and RSI — The Loop Nobody Has Closed (2026-09-13); Daily Pulse: The Opex Handover — Why the AI Trade Is Rotating, Not Rolling Over (2026-06-30). What Closelooknet said most recently: The International AI Safety Report 2026 devotes a section to it, and ICLR 2026 ran a workshop with recursive self-improvement in the title. (Report, 2026-09-13). The "Mentioned on Closelooknet" block on this page lists the long reads, the reference entries and the dailies that name it.

What does ICON PLC do?

ICON runs outsourced clinical trial and drug development work for pharmaceutical, biotech and device companies, covering the full path from early compound testing through Phase I-IV studies. It also offers laboratory testing, data analysis, site and patient access, and post-approval commercial support. It is headquartered in Dublin and serves clients across pharmaceuticals, biotechnology, devices and public health bodies. Closelooknet's peer group for ICON is not defined in our records; the market commonly compares it with IQVIA as another large clinical research organisation. (Company snapshot of 2026-09-17.)

Where does ICON PLC sit in the AI build-out?

ICON carries no seat in our Rubin or Halo indices and sits outside the AI build-out sleeves; the diary places it in the healthcare sector, under diagnostics and research, alongside other clinical research organisations rather than any chip, compute or data-centre layer. ICON carries a Closelooknet score, but only one module has been scored so far, so the reading is still being built. It has no index seat and appears in two editions, though both quotes concern the ICLR machine-learning conference rather than the company itself, a name overlap rather than dedicated coverage of its business. (Company snapshot of 2026-09-17.)

Does ICON PLC pay a dividend?

No cash distribution shows in ICON PLC’s price series over the last three years. In fiscal 2025 the company bought back 750 m USD of its own shares, 87% of that year’s free cash flow. The share count fell 4.9% over the fiscal year. As of 2026-10-30; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on ICON PLC recently?

The most recent analyst action on ICON PLC on the Closelooknet wire is a price target by Mizuho on 2026-10-30 (target 228). 10 actions on the analyst wire since 2026-08-13: 10 target changes. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for ICLR, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Diagnostics & Research. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.